Durable Weight Loss Follows Just a Few Injections of Novel Drug
A once-monthly injectable weight management medication safely induced long-term weight loss in a phase I human experiment.
At the maximum dose tested, people with overweight or obesity lost 14.5% of their body weight by day 85.
Murielle Véniant, PhD, of Amgen Research in Thousand Oaks, California, and colleagues reported in Nature Metabolism, which opens in a new tab or window.
At 150 days after the last dosage, this high-dose group maintained an 11.2% weight decrease from baseline.
Maridebart cafraglutide, also known as MariTide and earlier as AMG 133, is a first-in-class experimental drug that inhibits the stomach inhibitory polypeptide receptor (GIPR) while
"The combination of an anti-GIPR monoclonal antibody ... and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models,"
They noted that because the chemical has a longer half-life than other similar medicines on the market, dosing intervals can be increased while still achieving the majority of the
Current GLP-1 receptor agonists on the market for weight reduction, such as semaglutide (Wegovy)opens in a new tab or window and tirzepatide (Zepbound), are injected once weekly an
Love Horoscope For February 1, 2024 Brings ChangeFor More WebStories